Table 1 Differences in the mortality rate and noradrenaline-free days between the patients in the PMX-HP-treated group and the control group stratified by SOFA score
|
28-day mortality range (%) Fatality/the number of patients (n) |
Noradrenaline-free days Median (IQR) | |||||
|---|---|---|---|---|---|---|
| SOFA score range | PMX-HP group | Control group | p-value | PMX-HP group | Control group | p-value |
| 0–6 |
15.0–15.2 (69/456) |
9.1–16.7 (47/407) | NS | 25 (21-–6) | 25 (20–26) | 0.9287 |
| 7–9 |
14.2–16.1 (83/553) |
16.2–22.9 (92/463) | 0.0410 | 25 (20–26) | 24 (11–26) | 0.0003 |
| 10–12 |
14.8–25.3 (95/510) |
25.3–30.6 (145/529) | 0.0008 | 24 (15–26) | 22(0–6) | 0.0005 |
| 13–15 |
28.5–39.3 (116/356) |
24.8–35.5 (118/404) | NS | 22 (0–25) | 21.5 (0–25) | 0.9161 |
| 16–24 |
30.6–61.5 (62/158) |
34.6–57.1 (96/230) | NS | 14 (0–24) | 15 (0–4) | 0.3491 |